TY - JOUR
T1 - Natural history of multiple myeloma with de novo del(17p)
AU - Lakshman, Arjun
AU - Painuly, Utkarsh
AU - Rajkumar, S. Vincent
AU - Ketterling, Rhett P.
AU - Kapoor, Prashant
AU - Greipp, Patricia T.
AU - Gertz, Morie A.
AU - Buadi, Francis K.
AU - Lacy, Martha Q.
AU - Dingli, David
AU - Dispenzieri, Angela
AU - Fonder, Amie L.
AU - Hayman, Suzanne R.
AU - Hobbs, Miriam A.
AU - Gonsalves, Wilson I.
AU - Hwa, Yi Lisa
AU - Leung, Nelson
AU - Go, Ronald S.
AU - Lin, Yi
AU - Kourelis, Taxiarchis V.
AU - Warsame, Rahma
AU - Lust, John A.
AU - Russell, Stephen J.
AU - Zeldenrust, Steven R.
AU - Kyle, Robert A.
AU - Kumar, Shaji K.
N1 - Publisher Copyright:
© 2019, The Author(s).
PY - 2019/3/1
Y1 - 2019/3/1
N2 - We compared the outcomes of 310 patients with newly diagnosed multiple myeloma with del(17p) detected by FISH to patients with high-risk translocations (HRT) (n = 79) and standard-risk (SR) cytogenetics (n = 541). The median progression-free survival (PFS) following initial therapy for the three groups was 21.1, 22, and 30.1 months, respectively (P = 0.437- del(17p) vs. HRT); the median overall survival (OS) was 47.3, 79.1, and 109.8 months, respectively, (P = 0.007- del(17p) vs. HRT). PFS and OS for patients with relative loss of 17p (n = 21) were comparable to other patients with del(17p). The PFS was similar between the del(17p) and HRT groups when stratified for age, ISS stage or treatment. The OS of del(17p) and HRT groups were similar in presence of advanced age, ISS III stage or if patients did not receive a proteasome-inhibitor containing induction. ISS III stage, high LDH and HRT, but not the percentage of cells with del(17p) predicted shorter OS in patients with del(17p). The median OS for low (ISS I, normal LDH and no HRT), intermediate (neither low nor high-risk) and high-risk (ISS III and either elevated LDH or coexistent HRT) groups among del(17p) patients were 96.2, 45.4, and 22.8 months, respectively, allowing further risk stratification.
AB - We compared the outcomes of 310 patients with newly diagnosed multiple myeloma with del(17p) detected by FISH to patients with high-risk translocations (HRT) (n = 79) and standard-risk (SR) cytogenetics (n = 541). The median progression-free survival (PFS) following initial therapy for the three groups was 21.1, 22, and 30.1 months, respectively (P = 0.437- del(17p) vs. HRT); the median overall survival (OS) was 47.3, 79.1, and 109.8 months, respectively, (P = 0.007- del(17p) vs. HRT). PFS and OS for patients with relative loss of 17p (n = 21) were comparable to other patients with del(17p). The PFS was similar between the del(17p) and HRT groups when stratified for age, ISS stage or treatment. The OS of del(17p) and HRT groups were similar in presence of advanced age, ISS III stage or if patients did not receive a proteasome-inhibitor containing induction. ISS III stage, high LDH and HRT, but not the percentage of cells with del(17p) predicted shorter OS in patients with del(17p). The median OS for low (ISS I, normal LDH and no HRT), intermediate (neither low nor high-risk) and high-risk (ISS III and either elevated LDH or coexistent HRT) groups among del(17p) patients were 96.2, 45.4, and 22.8 months, respectively, allowing further risk stratification.
UR - http://www.scopus.com/inward/record.url?scp=85062584929&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062584929&partnerID=8YFLogxK
U2 - 10.1038/s41408-019-0191-y
DO - 10.1038/s41408-019-0191-y
M3 - Article
C2 - 30846679
AN - SCOPUS:85062584929
SN - 2044-5385
VL - 9
JO - Blood cancer journal
JF - Blood cancer journal
IS - 3
M1 - 32
ER -